TransMedics Group Sees Unusually High Options Volume (NASDAQ:TMDX)

TransMedics Group, Inc. (NASDAQ:TMDX) was the target of some unusual options trading on Monday. Stock investors purchased 15,600 put options on the stock. This represents an increase of 603% compared to the typical volume of 2,219 put options.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. D.A. Davidson & CO. increased its position in TransMedics Group by 0.5% during the 4th quarter. D.A. Davidson & CO. now owns 15,334 shares of the company’s stock worth $1,865,000 after buying an additional 83 shares during the period. Parallel Advisors LLC grew its holdings in shares of TransMedics Group by 42.1% during the 4th quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock worth $34,000 after purchasing an additional 83 shares in the last quarter. HighPoint Advisor Group LLC grew its holdings in shares of TransMedics Group by 3.1% during the 4th quarter. HighPoint Advisor Group LLC now owns 2,955 shares of the company’s stock worth $359,000 after purchasing an additional 88 shares in the last quarter. Crossmark Global Holdings Inc. grew its holdings in shares of TransMedics Group by 4.0% during the 4th quarter. Crossmark Global Holdings Inc. now owns 2,275 shares of the company’s stock worth $277,000 after purchasing an additional 88 shares in the last quarter. Finally, Canada Pension Plan Investment Board grew its holdings in shares of TransMedics Group by 2.9% during the 2nd quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company’s stock worth $482,000 after purchasing an additional 100 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on TMDX shares. Piper Sandler reduced their price target on TransMedics Group from $160.00 to $120.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of TransMedics Group in a research report on Tuesday, June 9th. UBS Group reaffirmed a “hold” rating on shares of TransMedics Group in a research report on Tuesday, May 26th. Canaccord Genuity Group reduced their price target on TransMedics Group from $152.00 to $124.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. Finally, JPMorgan Chase & Co. upped their price target on TransMedics Group from $114.00 to $149.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 25th. Six analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $134.00.

TransMedics Group Stock Performance

TMDX stock traded up $1.95 during trading hours on Monday, hitting $74.86. 556,212 shares of the stock were exchanged, compared to its average volume of 1,092,630. The company has a current ratio of 6.74, a quick ratio of 6.19 and a debt-to-equity ratio of 1.70. The firm has a market capitalization of $2.59 billion, a P/E ratio of 17.05 and a beta of 1.92. The company has a 50-day simple moving average of $86.20 and a two-hundred day simple moving average of $115.01. TransMedics Group has a 12 month low of $60.10 and a 12 month high of $156.00.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $0.30 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.32). The firm had revenue of $173.93 million for the quarter, compared to the consensus estimate of $174.44 million. TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The firm’s quarterly revenue was up 21.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.70 EPS. On average, analysts forecast that TransMedics Group will post 1.98 earnings per share for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.